IFNL3
Basic information
Region (hg38): 19:39243455-39245250
Previous symbols: [ "IL28B" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Drug metabolism, IL28B-related | AD | Pharmacogenomic | Variants may have pharmacogenomic importance, as selection and dosing of medications (including peg-interferon and ribavirin) may be affected by the presence of variants | General | 19684573; 19749758; 19749757; 19759533; 21254158; 21993426; 21443535; 21951981 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IFNL3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 18 | 25 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 18 | 1 | 6 |
Variants in IFNL3
This is a list of pathogenic ClinVar variants found in the IFNL3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-39243660-C-T | not specified | Uncertain significance (Feb 27, 2024) | ||
19-39243672-C-T | not specified | Uncertain significance (Dec 07, 2021) | ||
19-39243681-A-C | not specified | Uncertain significance (Aug 17, 2021) | ||
19-39243682-G-A | not specified | Uncertain significance (Apr 28, 2023) | ||
19-39243712-C-T | Benign (Aug 08, 2018) | |||
19-39243825-T-G | not specified | Uncertain significance (Mar 27, 2023) | ||
19-39243829-T-C | not specified | Uncertain significance (Jul 05, 2023) | ||
19-39243839-C-G | not specified | Uncertain significance (Jan 04, 2024) | ||
19-39243843-A-G | not specified | Uncertain significance (Nov 13, 2023) | ||
19-39243850-G-A | Benign (Jul 16, 2018) | |||
19-39243861-T-C | not specified | Uncertain significance (May 09, 2024) | ||
19-39243865-G-A | not specified | Uncertain significance (Mar 27, 2023) | ||
19-39243867-C-T | not specified | Uncertain significance (Oct 03, 2022) | ||
19-39243873-C-T | not specified | Uncertain significance (Mar 11, 2022) | ||
19-39244094-T-C | Benign (Aug 16, 2018) | |||
19-39244133-C-G | Benign (Aug 16, 2018) | |||
19-39244143-G-A | not specified | Likely benign (Mar 26, 2024) | ||
19-39244148-G-A | not specified | Uncertain significance (Nov 01, 2022) | ||
19-39244283-A-G | peginterferon alfa-2b response - Efficacy • ribavirin response - Efficacy • peginterferon alfa-2a response - Efficacy | drug response (Mar 24, 2021) | ||
19-39244423-C-G | not specified | Uncertain significance (Nov 22, 2023) | ||
19-39244460-C-T | Benign (Aug 16, 2018) | |||
19-39244466-T-C | not specified | Likely benign (Mar 09, 2018) | ||
19-39244835-G-C | not specified | Uncertain significance (Feb 27, 2023) | ||
19-39244871-C-G | not specified | Uncertain significance (Dec 18, 2023) | ||
19-39244888-A-T | not specified | Uncertain significance (May 27, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IFNL3 | protein_coding | protein_coding | ENST00000413851 | 5 | 1401 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.42e-8 | 0.0443 | 125716 | 0 | 15 | 125731 | 0.0000597 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.16 | 158 | 122 | 1.30 | 0.00000758 | 1230 |
Missense in Polyphen | 23 | 24.97 | 0.92111 | 328 | ||
Synonymous | -0.453 | 60 | 55.7 | 1.08 | 0.00000347 | 436 |
Loss of Function | -1.01 | 10 | 7.09 | 1.41 | 3.01e-7 | 83 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000145 | 0.000145 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000327 | 0.000326 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000176 | 0.0000176 |
Middle Eastern | 0.000327 | 0.000326 |
South Asian | 0.0000665 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN- stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type- selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. {ECO:0000269|PubMed:12469119, ECO:0000269|PubMed:12483210}.;
- Pathway
- Jak-STAT signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);JAK-STAT-Core;Type III interferon signaling
(Consensus)
Recessive Scores
- pRec
- 0.101
Intolerance Scores
- loftool
- rvis_EVS
- 1.28
- rvis_percentile_EVS
- 93.77
Haploinsufficiency Scores
- pHI
- 0.0398
- hipred
- N
- hipred_score
- 0.112
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- gene_indispensability_score
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ifnl3
- Phenotype
- hematopoietic system phenotype; immune system phenotype;
Gene ontology
- Biological process
- JAK-STAT cascade;regulation of signaling receptor activity;cytokine-mediated signaling pathway;negative regulation of viral genome replication;innate immune response;positive regulation of immune response;defense response to virus
- Cellular component
- extracellular region;extracellular space
- Molecular function
- signaling receptor binding;cytokine activity